✦ LIBER ✦

An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer

✍ Scribed by Michael S. Simon; Miron Stano; Mohamed Hussein; Michael Hoff; Daryn Smith

Publisher: Springer US
Year: 1996
Tongue: English
Weight: 750 KB
Volume: 37
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01806630

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical surveillance for early stage br

Clinical surveillance for early stage breast cancer: An analysis of claims data

✍ Michael S. Simon; Miron Stano; Richard K. Severson; Michael S. Hoff; Daryn W. Sm 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 756 KB

Cost utility analysis of early adjuvant

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

✍ Jonathan Karnon; Thomas Delea; Vicki Barghout 📂 Article 📅 2007 🏛 Springer 🌐 French ⚖ 297 KB

An evaluation of clinical follow-up in w

An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology

✍ Michael S. Simon; Michael Hoff; Mohamed Hussein; Silvana Martino; Alexander Walt 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 796 KB

What is the significance of a lobular ca

What is the significance of a lobular carcinoma in situ (LCIS) component in women treated with breast conserving therapy (BCT) for early stage breast cancer?

✍ K.L. Griem; W.F. Hartsell; D.C. Recine; M.St. Julien; T.R. Witt; S. Binee; E. St 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 91 KB

The impact of tumor progesterone recepto

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer : A decision analysis

✍ Rinaa S. Punglia; Karen M. Kuntz; Eric P. Winer; Jane C. Weeks; Harold J. Burste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB